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identify such patients and thereby avoid unnecessary and costly
invasive procedures.
With regard to the randomized cohort, the comparable reduc-
tion in scintigraphic ischemia among the 2 strategies led to similar
1-year event rates. The crossover rates are similar to those reported
in other acute coronary syndrome trials and were comparable
between the two strategies. Although INSPIRE was underpow-
ered to categorically assess differences in event rates between
strategies, it provides event rate estimates for designing an ade-
quately powered outcome trial. The main INSPIRE trial results
give strong support for the premise that the presence and extent of
scintigraphic ischemia predict risk and are surrogate markers for
cardiac events.
Medical therapy is appropriate in all post-AMI patients, but it
is usually not maximized. In INSPIRE, most patients in both
randomized strategies received antiplatelet agents, beta-blockers,
and statins. However, INSPIRE was unique in mandating maxi-
mally tolerated doses of all classes of anti-ischemic medications to
patients in the medical-therapy limb. The objective was to mini-
mize scintigraphic ischemia—a goal achieved in the majority of
patients.
Both INSPIRE (1,2) and other recently published trials (3,4)
provide new evidence that a conservative approach of early risk
stratification through noninvasive imaging is not only reasonable
but appropriate in the majority of patients post-AMI so as to
identify those most likely to benefit from coronary revasculariza-
tion. Finally, INSPIRE also shows that in patients with ischemia
and preserved left ventricular function, intensive medical therapy is
an excellent initial treatment option.
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Hyperthyroidism and Mortality
Hyperthyroidism is associated with systemic inflammation (1)
atrial fibrillation (2), and vascular and left ventricular hypertrophy
(3,4). It is therefore reasonable to assume an increased mortality in
patients with overt hyperthyroidism compared to euthyroid sub-
jects. The effects of hyperthyroidism on all-cause and circulatory
mortality, however, are a matter of debate and subject to ongoing
controversy. Some investigations demonstrated increased mor-
tality in hyperthyroid compared to euthyroid subjects (5,6), but
others did not confirm this finding (7–9). One study even
revealed lower mortality in hyperthyroid compared to euthyroid
elderly subjects (10).
In a previous issue of JACC, Osman et al. (11) analyzed
mortality of 393 patients with overt hyperthyroidism and 393 age-
and gender-matched euthyroid subjects. During the 66.6 months
of follow-up, 26 patients died, 7 of them from circulatory causes,
whereas 12 euthyroid subjects died, 4 of them from circulatory
causes. Unfortunately, risk estimates, including levels of statistical
significance, were not given.
As correctly stated by Osman et al. (1), interpretation of their
results is hampered by the low number of deceased subjects.
Further limitations, however, should be considered and discussed.
First, a number of potential factors confound the association
between hyperthyroidism and mortality. Osman et al. (11) con-
trolled for gender and age by study design. In addition, imbalances
between hyperthyroid and euthyroid subjects with regard to
current smoking (29% vs. 15%, p  0.0001) and diabetes mellitus
(6% vs. 3%, p  0.1) will have strong effects on the group-specific
mortality risk in their study. Thus, analyses should also be
controlled for at least these 2 factors.
Second, the outcome in patients who undergo a specific treat-
ment depends upon various characteristics, including risk factors
for the disease, the disease itself, comorbidities influencing the
choice of a specific therapy, and desired and undesired treatment
effects. Increased mortality in patients with hyperthyroidism seen
in the study by Osman et al. (11) might therefore be explained at
least hypothetically by, for example, the type of and the indication
for a specific antithyroid therapy and the status of thyroid function
following treatment.
Third, Osman et al. (11) recruited patients with hyperthy-
roidism from a university hospital, whereas euthyroid subjects
were selected either from staff members working at the hospital
or from a community center. Patients referred to university
hospitals more often exhibit (not only cardiovascular) co-
morbidities than do ambulatory-treated patients or patients re-
ferred to general hospitals. Thus, patients with overt hyperthyroid-
ism recruited for this investigation (11) are probably not
representative of hyperthyroid patients living in the study region.
Likewise, with regard to control subjects, medical staff might in
general behave healthier than the rest of the population. As a
result, excess mortality among cases compared to controls might be
explained by selection bias.
Taken together, the association between overt hyperthyroidism
and mortality found in the study of Osman et al. (11) likely results
from bias and confounding and should not necessarily be inter-
preted as a biological, causal relationship.
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Reply
We thank Dr. Völzke for his comments on our recent publication
describing the cardiovascular manifestations of hyperthyroidism
before and after antithyroid therapy (1). This age- and gender-
matched case-control study of a consecutive series of 393 subjects
presenting with overt hyperthyroidism aimed to define the cardio-
vascular symptoms, signs, and dysrhythmias found in hyperthy-
roidism and to compare results with euthyroid control subjects.
After a mean follow-up period of 5.5 years after presentation, 26
hyperthyroid subjects had died compared with 12 age- and
gender-matched controls (p  0.01). We state in our discussion
that “the number of deaths remained too small to determine
whether excess mortality [not a primary end point of our study]
was specifically vascular in nature.” We agree that the higher
prevalence of smoking in our hyperthyroid subjects may be a
confounder in terms of the mortality observed; however, there was
no significant difference in prevalence of diabetes between subjects
and controls. Whereas Dr. Völzke asserts that our hyperthyroid
subjects may have been selected because they were seen in a
university hospital setting, we consider this unlikely as our hospital
serves as the general referral site for hyperthyroidism, rather than
as a specialist referral center.
In summarizing previous reports examining the relationship
between hyperthyroidism and mortality, Dr. Völzke failed to make
the critical distinction between studies of overt hyperthyroidism
and those examining subclinical hyperthyroidism (defined bio-
chemically as low serum thyrotropin with normal circulating
thyroid hormone concentrations). We have previously reported in
2 large cohort studies that overt hyperthyroidism is associated with
excess all-cause and vascular mortality (2,3) findings in accord with
a large cohort study in the U.S. (4) and together providing good
evidence that the cardiovascular complications of overt thyroid
hormone excess (1) translate into excess vascular mortality. Unsur-
prisingly, results are less clear-cut for subclinical hyperthyroidism,
which represents a much lesser degree of thyroid hormone excess.
Increasing evidence from several large studies supports a link
between subclinical hyperthyroidism and atrial fibrillation (5–7).
We have previously reported that a low serum thyrotropin result is,
in turn, associated with increased mortality after follow-up of 10
years (8) however, a higher rate of coronary heart disease and
all-cause mortality observed by Cappola et al. during follow-up of
subclinical hyperthyroidism was not significant (5). Likewise,
Walsh et al. (9) found no adverse outcomes in a prospective study
of subclinical hyperthyroid subjects (9).
A very different study in subjects aged 73 to 94 years by van den
Beld et al. (10)—incorrectly cited by Dr. Völzke as evidence
against an association between subclinical hyperthyroidism and
mortality—examined the relationship between circulating thyroid
hormone concentrations and physical performance scores, other
markers of muscle function, and bone density. That study revealed
an association between higher serum T4 and reduced physical
performance score. Gussekloo et al. (11) studied very elderly
subjects from the Leiden cohort (85 to 89 years) and reported
increased hazard ratios for mortality for increasing increments of
serum-free T4, as well as reduced mortality associated with
subclinical hypothyroidism, not hyperthyroidism as suggested by
Dr. Völzke.
*Michael D. Gammage, MD, FRCP, FESC
Faizel Osman, MD, MRCP
Michael C. Sheppard, PhD, FRCP
Jayne A. Franklyn, MD, PhD, FRCP
*University Hospital Birmingham
Cardiology
Edgbaston
Birmingham
West Midlands B15 2TH
United Kingdom
E-mail: m.d.gammage@bham.ac.uk
doi:10.1016/j.jacc.2007.03.021
REFERENCES
1. Osman F, Franklyn JA, Holder RL, Sheppard MC, Gammage MD.
Cardiovascular manifestations of hyperthyroidism before and after
antithyroid therapy: a matched case-control study. J Am Coll Cardiol
2007;49:71–81.
2. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P.
Mortality after the treatment of hyperthyroidism with radioactive
iodine. N Engl J Med 1998;338:712–8.
2229JACC Vol. 49, No. 22, 2007 Correspondence
June 5, 2007:2227–30
